[go: up one dir, main page]

AR095620A1 - CONTROLLED RELEASE FORM FOR THE ADMINISTRATION OF FLUOROQUINOLONES FOR THE TREATMENT OF CHYSICAL FIBROSIS, PREPARATION PROCEDURE - Google Patents

CONTROLLED RELEASE FORM FOR THE ADMINISTRATION OF FLUOROQUINOLONES FOR THE TREATMENT OF CHYSICAL FIBROSIS, PREPARATION PROCEDURE

Info

Publication number
AR095620A1
AR095620A1 ARP140101245A ARP140101245A AR095620A1 AR 095620 A1 AR095620 A1 AR 095620A1 AR P140101245 A ARP140101245 A AR P140101245A AR P140101245 A ARP140101245 A AR P140101245A AR 095620 A1 AR095620 A1 AR 095620A1
Authority
AR
Argentina
Prior art keywords
controlled release
release form
administration
treatment
fibrosis
Prior art date
Application number
ARP140101245A
Other languages
Spanish (es)
Inventor
R Castro Guillermo
A Isln Germn
Original Assignee
Consejo Nac De Investig Científicas Y Técnicas (Conicet)
Univ Nac De La Plata (Unlp)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac De Investig Científicas Y Técnicas (Conicet), Univ Nac De La Plata (Unlp) filed Critical Consejo Nac De Investig Científicas Y Técnicas (Conicet)
Priority to ARP140101245A priority Critical patent/AR095620A1/en
Publication of AR095620A1 publication Critical patent/AR095620A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formas de liberación controlada para la administración de antibióticos para el tratamiento de la fibrosis quística. Provee una forma de liberación controlada con una alta eficiencia de encapsulación de un antibiótico de la familia de las fluoroquinolonas y una enzima capaz de hidrolizar el alginato ambos co-inmovilizados en una matriz basada en un biopolímero polisacárido. Reivindicación 1: Una forma de liberación controlada, caracterizada porque comprende un antibiótico y una enzima hidrolasa, ambos co-inmovilizados en una matriz basada en micropartículas de un biopolímero de polisacárido. Reivindicación 4: Una forma de liberación controlada de acuerdo con la reivindicación 3, caracterizada porque dicho antibiótico es ciprofloxacina. Reivindicación 6: Una forma de liberación controlada de acuerdo con la reivindicación 1, caracterizada porque dicha enzima hidrolasa es una enzima alginato liasa de Flavobacterium sp o Sphingobacterium multivorum. Reivindicación 9: Una forma de liberación controlada de acuerdo con la reivindicación 8, caracterizada porque dicho biopolímero se selecciona del grupo formado por pectinas de alto grado de metoxilación.Forms of controlled release for the administration of antibiotics for the treatment of cystic fibrosis. It provides a controlled release form with high efficiency of encapsulation of an antibiotic of the fluoroquinolone family and an enzyme capable of hydrolyzing the alginate both co-immobilized in a matrix based on a polysaccharide biopolymer. Claim 1: A controlled release form, characterized in that it comprises an antibiotic and a hydrolase enzyme, both co-immobilized in a microparticle-based matrix of a polysaccharide biopolymer. Claim 4: A controlled release form according to claim 3, characterized in that said antibiotic is ciprofloxacin. Claim 6: A controlled release form according to claim 1, characterized in that said hydrolase enzyme is an enzyme alginate lyase of Flavobacterium sp or Sphingobacterium multivorum. Claim 9: A controlled release form according to claim 8, characterized in that said biopolymer is selected from the group consisting of high-grade methoxylation pectins.

ARP140101245A 2014-03-17 2014-03-17 CONTROLLED RELEASE FORM FOR THE ADMINISTRATION OF FLUOROQUINOLONES FOR THE TREATMENT OF CHYSICAL FIBROSIS, PREPARATION PROCEDURE AR095620A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP140101245A AR095620A1 (en) 2014-03-17 2014-03-17 CONTROLLED RELEASE FORM FOR THE ADMINISTRATION OF FLUOROQUINOLONES FOR THE TREATMENT OF CHYSICAL FIBROSIS, PREPARATION PROCEDURE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP140101245A AR095620A1 (en) 2014-03-17 2014-03-17 CONTROLLED RELEASE FORM FOR THE ADMINISTRATION OF FLUOROQUINOLONES FOR THE TREATMENT OF CHYSICAL FIBROSIS, PREPARATION PROCEDURE

Publications (1)

Publication Number Publication Date
AR095620A1 true AR095620A1 (en) 2015-10-28

Family

ID=56119126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101245A AR095620A1 (en) 2014-03-17 2014-03-17 CONTROLLED RELEASE FORM FOR THE ADMINISTRATION OF FLUOROQUINOLONES FOR THE TREATMENT OF CHYSICAL FIBROSIS, PREPARATION PROCEDURE

Country Status (1)

Country Link
AR (1) AR095620A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110772543A (en) * 2019-11-12 2020-02-11 浙江长生鸟健康科技股份有限公司 Preparation process of superfine pearl powder

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110772543A (en) * 2019-11-12 2020-02-11 浙江长生鸟健康科技股份有限公司 Preparation process of superfine pearl powder
CN110772543B (en) * 2019-11-12 2023-04-18 浙江长生鸟健康科技股份有限公司 Preparation process of superfine pearl powder

Similar Documents

Publication Publication Date Title
MX2022006525A (en) Lysin polypeptides active against gram-negative bacteria.
PH12016501671A1 (en) Novel polysaccharide and uses thereof
EP4233898A3 (en) Influenza mrna vaccines
CL2016001101A1 (en) Alkylamide substituted pyridyl compounds useful as response modulators of il-12 and il-23 and / or ifnalfa
MX376105B (en) METHOD FOR PRODUCING L-AMINO ACIDS USING AN ALKALIPHIC BACTERIA.
EA201692031A1 (en) PHARMACEUTICAL COMPOSITION WITH ACTIVE ACTION WITH RESPECT TO CHRONIC BACTERIAL INFECTIONS
MX373309B (en) ANTIBIOTIC COMPOSITIONS OF CEFTOLOZAN.
CL2016002794A1 (en) Peptide vaccine comprising a mutant ras peptide and a chemotherapeutic agent
EA201692552A1 (en) MODIFIED MENICOCCOKED POLYPEPTIDES fHbp
CL2016002442A1 (en) Rnasa for use in the treatment or prevention of viral infections.
EA201992175A1 (en) COMPOSITIONS AND METHODS INCLUDING PROBIOTIC MOLECULES
WO2014184677A3 (en) Eye care devices and methods
BRPI1008821A2 (en) USE OF A SOURCE OF CHLORINE DIOXIDE
PH12016500465B1 (en) Deoxynojirimycin derivatives and methods of their using
MX2016012248A (en) Compositions for the treatment of autodigestion.
CL2016000672A1 (en) Isolated bacterium of the genus streptomyces
AR095620A1 (en) CONTROLLED RELEASE FORM FOR THE ADMINISTRATION OF FLUOROQUINOLONES FOR THE TREATMENT OF CHYSICAL FIBROSIS, PREPARATION PROCEDURE
BR112018007474A2 (en) ? cleaning water filtration membranes?
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EA201591899A1 (en) INTRODUCTION NSAID AND RELATED COMPOSITIONS, METHODS AND SYSTEMS
EA201700254A1 (en) COMBINATION
MA49960A (en) HIGH CONCENTRATED, LOW VISCOSITY MASP-2 INHIBITOR ANTIBODY FORMULATIONS, KITS AND METHODS OF TREATMENT OF SUBJECTS WITH ATYPICAL HEMOLYTIC SYNDROME
WO2020022975A3 (en) New pharmaceutical compositions in the treatment of copd
BR112018012821A2 (en) glycoinhibitor to prevent adhesion of streptococcus in fish, and, use of a composition.
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase

Legal Events

Date Code Title Description
FB Suspension of granting procedure